



PATENT #10

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF MAILING

I hereby certify that this RESPONSE TO NOTICE TO COMPLY and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date indicated below with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

Ariel Fletcher

10/18/2002

Date of Deposit

Applicant: Burton, et al.)	
)	Group Art Unit: 1648
Serial No.: 10/016,986)	
)	Examiner: Unassigned
Filed: December 12, 2001)	
)	
Title: HUMAN NEUTRALIZING MONOCLONAL)	Our Ref.: TSRI 313.2 C1
ANTIBODIES TO HUMAN)	
IMMUNODEFICIENCY VIRUS)	
)	

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO
ACID SEQUENCE DISCLOSURES (37 CFR §1.821-1.825)**

RECEIVED

OCT 28 2002

TECH CENTER 1600/2900

Assistant Commissioner for Patents
Box Sequence, P.O. Box 2327
Arlington, VA 22202

Dear Sir:

In response to the enclosed copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures Under 37 CFR §1.821-1.825 mailed August 5, 2002, enclosed is a Sequence Listing on paper copy, made in accordance with 37 CFR §1.821 - §1.825. Also enclosed is the Sequence Listing in computer readable form, submitted as required by 37 CFR §1.821(e), on which the Sequence Listing is labeled 313.2CON1.

Applicants respectfully request entry of the Sequence Listing and computer readable copy thereof.

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR §1.821(a) through (c) and (e), respectively, are the same and include no new matter.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that making willful false statements and the like is punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Entry of the following amendment is respectfully requested.

Please amend the above-identified application as follows:

In The Specification:

At page 10, line 3, please substitute the following paragraph for the previous version:

Figure 5 illustrates the dicistronic expression vector, pComb, in the form of a phagemid expression vector. The amino acid residue sequence of the decapeptide tag and the Pel B leader sequence/spacer are listed in SEQ ID NOs: 5 and 6, respectively. The amino acid residue sequence of the leader sequence in the lower panel is listed in SEQ ID NO:7.